You just read:

Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

News provided by

Cell Therapeutics, Inc.

Dec 03, 2010, 01:30 EST